EHS
EHS

Albumin, liver stiffness after DAA therapy for HCV stratify liver cancer risk

Albumin levels and liver stiffness measurements taken during direct-acting antiviral therapy follow-up can stratify liver cancer risk among patients with hepatitis C and compensated advanced chronic liver disease, according to study results.
“Due to their safety profile and low side effects, any patient in any stage of chronic liver disease (from mild fibrosis to decompensated cirrhosis) can be treated with DAA,” Mònica Pons, MD, from the Vall d’Hebron Research Institute in Barcelona, Spain, and colleagues wrote. “Therefore, it is important to know which patients will

Source link

EHS
Back to top button